Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Octave Bioscience announced the appointment of Kirk Stockwood as Senior Vice President, Commercial on January 8, 2026.
Stockwood will lead commercial strategy as Octave scales its precision neurology platform. He brings over 20 years of specialty diagnostics experience and was most recently Vice President of Sales at Quanterix, where he led a global neurology and immunology team that delivered 12 consecutive quarters of double-digit revenue growth. His prior roles include commercial expansion work at Natera (NASDAQ: NTRA), 10x Genomics, Veritas Genetics, and Color Genomics. Leadership statements highlight his mandate to accelerate Octave’s commercial reach and advance its biomarker-driven solutions for multiple sclerosis and Parkinson’s disease.
Summary not available.
Natera (NASDAQ: NTRA) will present updated analyses from the phase III ALTAIR trial at ASCO GI (Jan 8–10, 2026). A post‑hoc blinded central radiographic review reclassified cases and showed a statistically significant disease‑free survival (DFS) benefit for Trifluridine/Tipiracil (FTD/TPI) versus placebo in Signatera‑positive colorectal cancer patients (median DFS 9.23 vs 5.55 months; HR 0.75, 95% CI: 0.55–0.98; P=0.0406). This result updates a prior overall ALTAIR analysis that was numerically improved but not statistically significant. Natera will also present data on Signatera velocity showing ~40% shorter RFS with ctDNA doubling ≤1 month.
Natera (NASDAQ: NTRA) launched an expanded 21-gene Fetal Focus single-gene NIPT powered by LinkedSNP technology, backed by prospective blinded data from the EXPAND trial.
In 294 total samples across 21 genes, the test demonstrated 96% sensitivity (24/25 affected pregnancies) and 98% population-weighted specificity. In a new 193-sample cohort covering 16 added genes, Fetal Focus showed 100% sensitivity (14/14) and 94.2% observed specificity. EXPAND has enrolled >1,800 participants and includes diagnostic confirmation for all positive and negative cases. The test is presented as an option when partner carrier testing is unavailable after a positive carrier screen.
Natera (NASDAQ: NTRA) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 13, 2026 at 4:30 p.m. PT (7:30 p.m. ET). Management will deliver a presentation and host a Q&A with the investment community. A live webcast will be available via the company's investor relations site at investor.natera.com, and a replay will be posted shortly after the event.
Natera (NASDAQ: NTRA) announced publication in JAMA Oncology of a randomized phase III CALGB (Alliance)/SWOG 80702 analysis of Signatera ctDNA in stage III colorectal cancer (940 patients with post-surgical plasma). Key findings: in Signatera-positive patients, adding celecoxib to FOLFOX lowered recurrence and death risk by ~40% (DFS adjusted HR=0.61; OS adjusted HR=0.62) with 3-year DFS 41.0% vs 22.6% and 5-year OS 61.6% vs 39.9%. No significant benefit was seen in Signatera-negative patients. A QC-restricted subgroup (66%) showed stronger benefit (adjusted HR=0.49); Natera reports 99% routine QC pass rate.
Natera (NASDAQ: NTRA) and collaborators published I‑SPY 2 results in Nature Communications showing Signatera personalized ctDNA testing can refine risk stratification in 723 women with high‑risk, early‑stage breast cancer treated with neoadjuvant therapy (NAT).
Key findings: Signatera improved prognostic precision beyond residual cancer burden (RCB) for RCB‑II/III patients; post‑NAT ctDNA– patients had substantially higher 3‑year distant recurrence‑free survival (e.g., RCB‑II T3 88% vs 57%; RCB‑III T3 83% vs 22% for ctDNA– vs ctDNA+). Persistent post‑NAT ctDNA+ predicted recurrence (adjusted HR 5.20, p < 0.001). Median assay variant conservation was 94–97% between pretreatment and post‑NAT samples.
Natera (NASDAQ: NTRA) and MEDSIR announced the MiRaDoR phase II multicenter trial (NCT05708235) testing Signatera Genome‑guided interventions in early‑stage HR+/HER2‑ breast cancer.
Up to 60 Signatera‑positive patients without radiologic recurrence will be sequentially assigned to four arms: standard endocrine therapy (90 days) then switch to Arm B giredestrant, Arm C giredestrant+abemaciclib, or Arm D giredestrant+inavolisib for PIK3CA‑mutant patients. Primary endpoint: proportion with ≥90% ctDNA decrease/clearance at 3 months. Enrollment is underway with UK sites active and further European activations expected in 2026.
Natera (NASDAQ: NTRA) reported initial translational results from the Phase III PALLAS trial showing that Signatera MRD testing after surgery strongly stratifies distant recurrence risk in stage II–III HR+/HER2- breast cancer.
In a U.S. biomarker cohort of 420 patients, ~92% were MRD-negative at baseline with a 5-year DRFI of 93%, while baseline MRD-positive (~8%) had a 5-year DRFI of 28% (HR ~15). At end of treatment, MRD-negative 5-year DRFI was 95% and MRD-positive 32% (HRs >20). MRD status at baseline, ~6 months, and EOT was consistently highly prognostic versus clinicopathologic factors.
Natera (NASDAQ: NTRA) presented two oral analyses at the ASH Annual Meeting showing clinical utility of personalized ctDNA testing in lymphoma.
Key highlights: Signatera detected ctDNA pre-treatment in 94% of 144 patients across 14 lymphoma subtypes and showed ctDNA clearance strongly predicted CAR-T response (p=0.0028); rapid clearance after one chemotherapy cycle had HR 20.95 versus 7.45 for delayed clearance. Signatera end-of-1L status was highly prognostic for event-free survival (HR 49.77, p<0.0001). The HOVON study using CLARITY (166 DLBCL patients) found post-negative surveillance relapse-free probability of 99% at 6 months and 97% at 12 months.